Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carol Reid

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Arthritis and Rheumatism|March 2, 2011
Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosisAriane L Herrick, Frank van den Hoogen, Armando Gabrielli, et al.
Advances in Health Sciences Education : Theory and Practice|June 10, 2022
The implementation of interprofessional education: a scoping reviewFiona Bogossian, Karen New, Kendall George, et al.
British Journal of Haematology|November 1, 2007
Outreach monitoring service for patients with indolent B-cell and plasma cell disorders: a UK experienceAndy C Rawstron, Richard A Jones, Carol Ferguson, et al.
The Journal of Adolescent Health : Official Publication of the Society for Adolescent Medicine|December 23, 2006
Bone mineral density in postmenarchal adolescent girls in the United States: associated biopsychosocial variables and bone turnover markersZeev Harel, Melanie Gold, Barbara Cromer, et al.
The Cochrane Database of Systematic Reviews|May 5, 2023
Interventions from pregnancy to two years after birth for parents experiencing complex post-traumatic stress disorder and/or with childhood experience of maltreatmentKimberley A Jones, Isabella Freijah, Sue E Brennan, et al.
Biological Psychiatry|January 25, 2017
Bitopertin in Negative Symptoms of Schizophrenia-Results From the Phase III FlashLyte and DayLyte StudiesDragana Bugarski-Kirola, Thomas Blaettler, Celso Arango, et al.
Neuromuscular Disorders : NMD|November 28, 2020
Long-term follow-up of patients with type 2 and non-ambulant type 3 spinal muscular atrophy (SMA) treated with olesoxime in the OLEOS trialFrancesco Muntoni, Enrico Bertini, Giacomo Comi, et al.
JAMA Neurology|May 12, 2025
Quantitative Muscle Magnetic Resonance Outcomes in Patients With Duchenne Muscular Dystrophy: An Exploratory Analysis From the EMBARK Randomized Clinical TrialKrista Vandenborne, Glenn A Walter, Volker Straub, et al.
The Lancet. Neurology|May 3, 2017
Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trialEnrico Bertini, Eric Dessaud, Eugenio Mercuri, et al.
Annals of Neurology|August 4, 2023
Delandistrogene Moxeparvovec Gene Therapy in Ambulatory Patients (Aged ≥4 to <8 Years) with Duchenne Muscular Dystrophy: 1-Year Interim Results from Study SRP-9001-103 (ENDEAVOR)Craig M Zaidman, Crystal M Proud, Craig M McDonald, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Arthritis and Rheumatism|March 2, 2011
Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosisAriane L Herrick, Frank van den Hoogen, Armando Gabrielli, et al.
Advances in Health Sciences Education : Theory and Practice|June 10, 2022
The implementation of interprofessional education: a scoping reviewFiona Bogossian, Karen New, Kendall George, et al.
British Journal of Haematology|November 1, 2007
Outreach monitoring service for patients with indolent B-cell and plasma cell disorders: a UK experienceAndy C Rawstron, Richard A Jones, Carol Ferguson, et al.
The Journal of Adolescent Health : Official Publication of the Society for Adolescent Medicine|December 23, 2006
Bone mineral density in postmenarchal adolescent girls in the United States: associated biopsychosocial variables and bone turnover markersZeev Harel, Melanie Gold, Barbara Cromer, et al.
The Cochrane Database of Systematic Reviews|May 5, 2023
Interventions from pregnancy to two years after birth for parents experiencing complex post-traumatic stress disorder and/or with childhood experience of maltreatmentKimberley A Jones, Isabella Freijah, Sue E Brennan, et al.
Biological Psychiatry|January 25, 2017
Bitopertin in Negative Symptoms of Schizophrenia-Results From the Phase III FlashLyte and DayLyte StudiesDragana Bugarski-Kirola, Thomas Blaettler, Celso Arango, et al.
Neuromuscular Disorders : NMD|November 28, 2020
Long-term follow-up of patients with type 2 and non-ambulant type 3 spinal muscular atrophy (SMA) treated with olesoxime in the OLEOS trialFrancesco Muntoni, Enrico Bertini, Giacomo Comi, et al.
JAMA Neurology|May 12, 2025
Quantitative Muscle Magnetic Resonance Outcomes in Patients With Duchenne Muscular Dystrophy: An Exploratory Analysis From the EMBARK Randomized Clinical TrialKrista Vandenborne, Glenn A Walter, Volker Straub, et al.
The Lancet. Neurology|May 3, 2017
Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trialEnrico Bertini, Eric Dessaud, Eugenio Mercuri, et al.
Annals of Neurology|August 4, 2023
Delandistrogene Moxeparvovec Gene Therapy in Ambulatory Patients (Aged ≥4 to <8 Years) with Duchenne Muscular Dystrophy: 1-Year Interim Results from Study SRP-9001-103 (ENDEAVOR)Craig M Zaidman, Crystal M Proud, Craig M McDonald, et al.
Pageof 5